Conference Coverage

Experimental drug may boost executive function in patients with Alzheimer’s disease

Publish date: April 4, 2022

 

FROM AAN 2022

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Dietary fiber tied to lower dementia risk
MDedge Neurology
Amazonian indigenous groups have world’s lowest rate of dementia
MDedge Neurology
New guidance on palliative care for neurologic disorders
MDedge Neurology
FDA clears once-weekly transdermal patch for Alzheimer’s
MDedge Neurology
Restoring ‘sixth sense’ may reduce falls in Alzheimer’s
MDedge Neurology
Aducanumab and ARIA: Does the FDA’s prescribing label put patients at risk?
MDedge Neurology
Neuropsychiatric outcomes similar for hospitalized COVID-19 patients and non–COVID-19 patients
MDedge Neurology
Psychotropic med use tied to ‘striking’ post-COVID dementia risk
MDedge Neurology
Does evidence support benefits of omega-3 fatty acids?
MDedge Neurology
More evidence that COVID ‘brain fog’ is biologically based
MDedge Neurology